miR-29b as an Anti-Fibrotic Therapeutic: Mechanisms, Disease Biology and Translational Opportunities
Cells · 17.08.2026 · 15 (16) · 1472
DOI: 10.3390/cells15161472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 17.08.2026. Verfasst von Lee Armstrong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Genomic Medicine, Ulster University, Coleraine BT52 1SA, UK. Hauptthemen laut MEDLINE: MicroRNAs, Fibrosis, Translational Research, Biomedical. Die Arbeit nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Glaucoma uk.
Abstract (Originalsprache)
Fibrosis emerges when normally self-limiting tissue repair fails to resolve and overlapping phases of injury, stromal activation, extracellular matrix (ECM) deposition and remodelling become sustained. MicroRNAs (miRNAs) shape this transition by coordinating signalling, cell-state and matrix programmes. Functionally, pro-fibrotic fibro-miRs amplify fibrogenic pathways, whereas anti-fibrotic miRNAs restrain fibroblast activation and ECM production; the miR-29 family is a principal member of the latter group. This review examines miR-29 family organisation, the regulation of miR-29b by transforming growth factor-β (TGF-β)/Smad and additional transcriptional and inflammatory inputs, and the molecular targets through which miR-29b controls collagen synthesis, processing and crosslinking. Direct canonical targets are distinguished from experimentally supported, predicted and indirect pathway components. Evidence is evaluated across fibroblasts and myofibroblasts, epithelial and endothelial cells, and pulmonary, hepatic, renal, cardiac, dermal and ocular fibrosis models. Therapeutic translation is considered in relation to miR-29b mimics and agomirs, local and tissue-targeted delivery, pharmacokinetics, dose control, off-target repression, immune activation and long-term safety. Overall, miR-29b remains a credible network-level anti-fibrotic candidate, but successful translation requires cell- and disease-specific target validation, selective delivery and preservation of physiological wound repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Genomic Medicine, Ulster University, Coleraine BT52 1SA, UK.
- School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine BT52 1SA, UK.
ORCID-Profile: Declan J McKenna, Eva Mihalovova, Anton W Roodnat, Bridgeen Callan, Colin E Willoughby
Förderung
- Glaucoma uk
Zitieren
APA
Armstrong, L., McKenna, D. J., Mihalovova, E., Gribben, R. D., Roodnat, A. W., Callan, B., & Willoughby, C. E. (2026). miR-29b as an Anti-Fibrotic Therapeutic: Mechanisms, Disease Biology and Translational Opportunities. Cells, 15(16), 1472. https://doi.org/10.3390/cells15161472
Vancouver
Armstrong L, McKenna DJ, Mihalovova E, Gribben RD, Roodnat AW, Callan B, et al. miR-29b as an Anti-Fibrotic Therapeutic: Mechanisms, Disease Biology and Translational Opportunities. Cells. 2026;15(16):1472. doi:10.3390/cells15161472
BibTeX
@article{Armstrong2026,
author = {Armstrong, Lee and McKenna, Declan J and Mihalovova, Eva and Gribben, Roise D and Roodnat, Anton W and Callan, Bridgeen and Willoughby, Colin E},
title = {miR-29b as an Anti-Fibrotic Therapeutic: Mechanisms, Disease Biology and Translational Opportunities},
journal = {Cells},
year = {2026},
volume = {15},
number = {16},
pages = {1472},
doi = {10.3390/cells15161472}
}
EUVIMED